




# PHARMACEUTICAL 2018

CorMedix Inc.  
Rank 307 of 342





RealRate

# PHARMACEUTICAL 2018

CorMedix Inc.  
Rank 307 of 342



The relative strengths and weaknesses of CorMedix Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CorMedix Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 26% points. The greatest weakness of CorMedix Inc. is the variable Net Income, reducing the Economic Capital Ratio by 214% points.

The company's Economic Capital Ratio, given in the ranking table, is -209%, being 255% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	13,268
Cost of Goods Sold	115
Intangible Assets	0
Liabilities, Current	6,261
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	17
Other Expenses	86
Other Liabilities	0
Other Net Income	0
Other Revenues	329
Property and Equipment	186
Research and Development	24,486
Selling, General and Administrative Expense	8,652

Output Variable	Value in 1000 USD
Assets	13,454
Liabilities	6,261
Expenses	33,339
Revenues	329
Stockholders Equity	7,193
Net Income	-33,010
Comprehensive Net Income	-33,001
Economic Capital Ratio	-209%